2023 World Conference on Lung Cancer (Posters)-EP12.01. Case Report of Short-Term Gefitinib Induced IgA Nephropathy and Tubulointerstitial Nephritis in a Patient with Non-small Cell Lung Cancer

EP12.01. Case Report of Short-Term Gefitinib Induced IgA Nephropathy and Tubulointerstitial Nephritis in a Patient with Non-small Cell Lung Cancer - PDF(Slides)

Back to course

Pdf Summary

Gefitinib is a commonly used treatment for non-small cell lung cancer, but it can cause a range of adverse effects including skin rashes, diarrhea, and interstitial lung disease. While there have been few reports of renal toxicity, a case report from Jeju National University Hospital in South Korea describes a patient who developed IgA nephropathy and tubulointerstitial nephritis after taking gefitinib for six weeks. The patient's renal function worsened despite discontinuing the medication and required hospitalization. A kidney biopsy confirmed the diagnosis, and the patient was treated with steroids. Fortunately, the renal function slowly improved after stopping gefitinib and switching to another medication. <br /><br />Renal failure is rare with gefitinib treatment, and EGFR-TKIs are generally considered safe for patients with renal impairment. However, there have been reports of glomerular injuries associated with gefitinib, including minimal change disease and membranous nephropathy. The case report highlights the need for further studies on how to manage EGFR-TKI-induced renal impairment and determine the optimal duration of treatment. <br /><br />In summary, gefitinib, a first-generation EGFR-TKI, can cause adverse effects such as skin rashes and diarrhea. While renal toxicity is rare, this case report describes a patient who developed IgA nephropathy and tubulointerstitial nephritis after taking gefitinib for six weeks. The patient's renal function improved after discontinuing gefitinib and receiving steroid treatment. More research is needed to better understand and manage EGFR-TKI-induced renal impairment.

Asset Subtitle

Jieun Yang

Meta Tag

Speaker Jieun Yang

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

gefitinib

non-small cell lung cancer

adverse effects

skin rashes

diarrhea

renal toxicity

IgA nephropathy

tubulointerstitial nephritis

steroids

renal function